{
    "clinical_study": {
        "@rank": "26723", 
        "arm_group": [
            {
                "arm_group_label": "YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)", 
                "arm_group_type": "Experimental", 
                "description": "6 arm, 3 Sequence design\nYH4808 or Diclofenac or YH4808+Diclofenac\n3 week wash out period is between each period."
            }, 
            {
                "arm_group_label": "YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)", 
                "arm_group_type": "Experimental", 
                "description": "6 arm, 3 Sequence design\nYH4808 or Diclofenac or YH4808+Diclofenac\n3 week wash out period is between each period."
            }, 
            {
                "arm_group_label": "YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)", 
                "arm_group_type": "Experimental", 
                "description": "6 arm, 3 Sequence design\nYH4808 or Diclofenac or YH4808+Diclofenac\n3 week wash out period is between each period."
            }, 
            {
                "arm_group_label": "YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)", 
                "arm_group_type": "Experimental", 
                "description": "6 arm, 3 Sequence design\nYH4808 or Diclofenac or YH4808+Diclofenac\n3 week wash out period is between each period."
            }, 
            {
                "arm_group_label": "YH4808 or Diclofenac or YH4808+Diclofenac (arm5)", 
                "arm_group_type": "Experimental", 
                "description": "6 arm, 3 Sequence design\nYH4808 or Diclofenac or YH4808+Diclofenac\n3 week wash out period is between each period."
            }, 
            {
                "arm_group_label": "YH4808 or Diclofenac or YH4808+Diclofenac (arm6)", 
                "arm_group_type": "Experimental", 
                "description": "6 arm, 3 Sequence design\nYH4808 or Diclofenac or YH4808+Diclofenac\n3 week wash out period is between each period."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare pharmacokinetics after single oral administration\n      of YH4808 and Diclofenac each separately versus coadministration of YH4808 and Diclofenac in\n      healthy male volunteers"
        }, 
        "brief_title": "Pharmacokinetic Drug Interaction Between YH4808 and Diclofenac", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male age 20 to 45 over 55kg with Ideal body weight(IBW)\n\n          -  No clinically important abnormal physical findings at the screening examination\n\n          -  Subject who has no congential, chronic disease and disease symptoms in medical\n             examination result\n\n          -  Subject who is judged to be eligible by principal inverstigator or sub-investigator\n             according to various reasons includiong ther abnorminal test results(clinical\n             laboratory test, 12-lead GCG etc)\n\n          -  Ability to communicate well with the inverstigator and to comply with the requremetns\n             of the entire study\n\n          -  Willingness to give written informed consent(prior to any study-related procedures\n             beinging performed) and to be able to adhere to the study restrictions and\n             examination schedule\n\n        Exclusion Criteria:\n\n          -  Suject who has history or presence of clinically significant diseases in liver,\n             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,\n             blood tumor, cardiovascular, urinary system, and mental disorder\n\n          -  Subject who is hypersensitive to components contained in YH4808 or declofenac or\n             related drug(ex. rebamipide, revaprazan, NSID etc)\n\n          -  Medical history of gastrointestinal disease or acid restraining surgery, gastric/\n             esophagus surgery(excluding appendectomy, hernia surgery)\n\n          -  Subject who has history of drug dependence or using that drug\n\n          -  Subject who had taken usual dose of any prescription durgs within 14 days before the\n             treatment or who had used usual dose of OTC drugs within 7 days before the treatment\n\n          -  Subject who participated in antoher clinical trial within 2 monthes before enrolling\n             in this study\n\n          -  subject who donated whole blood within 2 months or component blood within 1 month\n             before the treatment\n\n          -  Subject who drank over 21unit/week(1 unit= 10g of alcohol) or were not able to\n             refrain from drinking alcohol during study days\n\n          -  Subject who stopped smoking within 3 months before the treatment or  detected\n             cotinine in urine test\n\n          -  Subject with clinically significant observations considered as unsuitable based on\n             medical judgment by the investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876615", 
            "org_study_id": "YH4808-109"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm5)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm6)"
                ], 
                "description": "experimental drug", 
                "intervention_name": "YH4808", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm5)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm6)"
                ], 
                "description": "Depain tablet 25mg", 
                "intervention_name": "Diclofenac", 
                "intervention_type": "Drug", 
                "other_name": "Depain tablet 25mg"
            }, 
            {
                "arm_group_label": [
                    "YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm5)", 
                    "YH4808 or Diclofenac or YH4808+Diclofenac (arm6)"
                ], 
                "intervention_name": "YH4808+Diclofenac", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Diclofenac"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "safety/tolerability and pharmacokinetics/pharmacodynamics", 
        "lastchanged_date": "December 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Chungnam National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Open-Label, Single-dosing and Cross-over Clinical Trial to Investigate the Safety and Pharmacokinetic Drug-Drug Interaction of YH4808 and Diclofenac in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Chungnam National University Hospital", 
            "last_name": "Janghee Hong, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax of YH4808", 
                "safety_issue": "No", 
                "time_frame": "18 points up to Day 2 or Day 3"
            }, 
            {
                "measure": "AUClast of YH4808", 
                "safety_issue": "No", 
                "time_frame": "18 points up to Day 3"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUCinf of YH4808", 
                "safety_issue": "No", 
                "time_frame": "18 points up to Day 3"
            }, 
            {
                "measure": "AUCinf of Diclofenac", 
                "safety_issue": "No", 
                "time_frame": "16points up to Day 2"
            }, 
            {
                "measure": "t1/2 of YH4808", 
                "safety_issue": "No", 
                "time_frame": "18 points up to Day 3"
            }, 
            {
                "measure": "t1/2 of Diclofenac", 
                "safety_issue": "No", 
                "time_frame": "16 points up to Day 2"
            }, 
            {
                "measure": "Tmax of YH4808", 
                "safety_issue": "No", 
                "time_frame": "18 points up to Day 3"
            }, 
            {
                "measure": "Tmax of Diclofenac", 
                "safety_issue": "No", 
                "time_frame": "16 points up to Day 2"
            }, 
            {
                "measure": "Metabolic ratio", 
                "safety_issue": "No", 
                "time_frame": "18 points up to Day 3"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}